What You Deserve to Know About Weight Loss Surgery in 2026
With new medications making headlines, the most e!ective treatment for severe obesity is being overlooked. Here are the facts your doctor may not have shared with you.
By Mark A. Colquitt, MD, FACS, FASMBS · Bariatric Surgery, Knoxville, TN
If you’ve been living with obesity and exploring your options, you’ve almost certainly heard about GLP-1 medications like Ozempic, Wegovy, and Mounjaro. They’ve been featured on every news channel, in every magazine, and in countless social media posts. What you may not have heard is that there’s a treatment that works significantly better, costs less over time, lasts longer, and is safer than you probably think.
That treatment is bariatric surgery. And in 2026, it may be the most underutilized, misunderstood medical procedure in America.
This isn’t about pitting one treatment against another. Medications have helped millions of people, and they represent genuine progress in the fight against obesity. But you deserve to make your health decisions based on complete information—and right now,the full picture isn’t reaching most patients.
The Numbers Tell a Clear Story
Let’s start with what the research actually shows when we compare bariatric surgery to GLP-1 medications head-to-head.
A 2025 study published in the American Journal of Surgery followed patients with obesity over 10 years, comparing those who underwent bariatric surgery to those treated with GLP-1 receptor agonist medications. Surgery was associated with a 46% lower risk of overall cardiovascular disease, a 55% lower risk of heart failure, and a 36% lower risk of stroke.
Meanwhile, a comprehensive review in Obesity Surgery analyzing over 1.2 million procedures found that modern bariatric surgery has remarkably low complication rates. Sleeve gastrectomy—the most commonly performed bariatric procedure today—carries a perioperative mortality rate of 0.03–0.08%. To put that in perspective, that’s comparable to or lower than having your gallbladder removed.
What the Medication Commercials Don’t Tell You
GLP-1 medications are e!ective. That’s not in dispute. But the way they’re being marketed deserves scrutiny.
The weight loss percentages featured in television commercials come from the most favorable trial designs (STEP-1 and Surmount-1) and report raw numbers rather than placebo-adjusted figures. When you compare surgical outcomes in similar patient populations—using the more appropriate STEP-2 and Surmount-2 trials that studied patients with diabetes—surgery produces significantly greater weight loss.
There are other realities about medications that get less airtime:
Perhaps most importantly, bariatric surgery is a one-time event with lasting results. Research in Diabetologia has confirmed that substantial weight loss—most durably achieved through surgery—can produce long-term remission of type 2 diabetes, with the best outcomes in patients treated early in their disease course.
Why Isn’t Your Doctor Talking About This?
If surgery is so e!ective, why isn’t it being recommended more o”en? There are several reasons, and none of them have to do with the quality of the evidence.
Pharmaceutical marketing is extraordinarily powerful. Novo Nordisk and Eli Lilly have advertising budgets that dwarf anything the surgical community could ever match. When your doctor sees ads in every medical journal and hears about GLP-1 benefits at every conference, it shapes prescribing patterns—even among well-intentioned physicians.
Many physicians’ understanding of bariatric surgery is outdated. The bariatric surgery of the 1990s and early 2000s was a very di!erent field. Open surgeries with long hospital stays and higher complication rates are a thing of the past. Today’s procedures are performed laparoscopically or robotically, o”en take less than an hour, and most patients go home the next day. But outdated perceptions persist.
Writing a prescription is faster than making a referral. In a busy primary care practice, it’s simply easier for your doctor to prescribe a medication than to spend time discussing surgical options, make a referral, and coordinate care with a bariatric team.
Only about 1% of patients who qualify for bariatric surgery ever receive it. That number hasn’t changed in decades—even as the evidence for surgery has grown dramatically stronger.
Surgery Has Never Been Safer
If you’ve been hesitant about surgery because of safety concerns, the data may surprise you. A landmark randomized clinical trial published in JAMA Network Open studied 1,735 patients and found zero 90-day mortality for both sleeve gastrectomy and gastric bypass. The serious adverse event rate was 1.7% for sleeve and 2.7% for bypass.
The comprehensive mortality review found that long-term all-cause mortality a”er bariatric surgery is 30–50% lower than in matched non-surgical patients. Cardiovascular mortality specifically was reduced by approximately 53%. In other words, having bariatric surgery doesn’t just help you lose weight—it helps you live longer.
Modern bariatric programs use multidisciplinary teams including surgeons, dietitians, psychologists, and exercise specialists. Enhanced recovery protocols mean less pain, shorter hospital stays, and faster return to your normal life than ever before.
Who Should Consider Surgery?
You may be a candidate for bariatric surgery if:
- You have a BMI of 35 or higher, or a BMI of 30–35 with obesity-related health conditions such as type 2 diabetes, high blood pressure, sleep apnea, or joint problems.
- You’ve tried other weight loss approaches without lasting success.
- You’ve been on GLP-1 medications but experienced significant side e!ects, couldn’t maintain them due to cost, or want a more permanent solution.
- You’re ready to commit to the lifestyle changes—nutrition, activity, and follow-up care—that make surgery most successful.
It’s also worth knowing that medications and surgery are not mutually exclusive. Emerging research shows that combining GLP-1 medications with bariatric surgery can produce even better outcomes than either approach alone, particularly in certain patient populations. The best bariatric programs today offer comprehensive obesity care that uses every available tool.
What Happens When Medications Stop Working?
Here’s a reality that isn’t discussed enough: the majority of patients who start GLP-1 medications will eventually stop them. Sometimes it’s the side e!ects. Sometimes it’s the cost. Sometimes the medication simply becomes less e!ective over time. When that happens, the weight typically returns.
If you find yourself in that situation—or if you’d rather address the problem once instead of managing it indefinitely—bariatric surgery deserves a place in the conversation. Not as a last resort, but as what the evidence consistently shows it to be: the most e!ective and durable treatment we have for obesity as a disease.
You Deserve a Complete Conversation
If you’re considering your weight loss options, don’t settle for incomplete information. Schedule a consultation with our Foothills Weight Loss Surgeons office in Knoxville, TN, to learn what bariatric surgery could mean for your health.
REFERENCES
- Maan S, et al. Metabolic and bariatric surgery versus GLP-1 receptor agonist therapy: A comparison of cardiovascular outcomes. Am J Surg. 2025;242:116242. DOI (Retrieved from PubMed, PMID: 39965476)
- Jumaev N, et al. Mortality A!er Bariatric Surgery: A Comprehensive Review. Obes Surg. 2025;35(11):4797-4805. DOI (Retrieved from PubMed, PMID: 41042299)
- Hedberg S, et al. Comparison of Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass: A Randomized Clinical Trial (BEST). JAMA Netw Open. 2024;7(1):e2353141. DOI (Retrieved from PubMed, PMID: 38289603)
- Rothberg A, Lean M, Laferrère B. Remission of type 2 diabetes: always more questions, but enough answers for action. Diabetologia. 2024;67(4):602-610. DOI (Retrieved from PubMed, PMID: 38189935)
Disclaimer: This article is for educational purposes and does not constitute medical advice. Individual results vary. Please consult with a qualified bariatric surgeon to determine if surgery is appropriate for your specific situation. All statistics cited are from peer-reviewed medical literature retrieved from PubMed.